Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Luca Potestio

Showing results (51-60 of 138) with videos related to

Pageof 14
Sort By:
Journal of Inflammation Research|February 19, 2026
IL-23 Inhibitors in Psoriasis: What Have We Learnt so Far?Matteo Megna, Michela D'Agostino, Federica Feo, et al.
Clinical, Cosmetic and Investigational Dermatology|February 13, 2023
Efficacy and Safety of Tildrakizumab in a Patient with Chronic HBV InfectionLuca Potestio, Ilaria Piscitelli, Gabriella Fabbrocini, et al.
Clinical and Experimental Dermatology|October 14, 2024
Impact of tildrakizumab on the quality of life of patients with moderate-to-severe psoriasis: a 36-week prospective monocentric real-life observational studySara Cacciapuoti, Teresa Battista, Luca Potestio, et al.
Clinical, Cosmetic and Investigational Dermatology|April 15, 2024
The Role of Interleukin 23/17 Axis in Psoriasis Management: A Comprehensive Review of Clinical TrialsLuca Potestio, Fabrizio Martora, Giuseppe Lauletta, et al.
Clinical and Experimental Dermatology|April 24, 2024
Efficacy and safety of bimekizumab in real-world psoriasis management: data from patients who are biologic-naive vs. biologic-experiencedMatteo Megna, Angelo Ruggiero, Ginevra Torta, et al.
Clinical, Cosmetic and Investigational Dermatology|March 13, 2024
Long-Term Efficacy of Guselkumab in an Adolescent Hidradenitis Suppurativa Patients: A Case ReportFabrizio Martora, Teresa Battista, Luca Potestio, et al.
Clinical, Cosmetic and Investigational Dermatology|June 4, 2024
Secukinumab for Severe Hidradenitis Suppurativa in a Patient on Haemodialysis: Efficacy and Safety on 300 mg Every 2 Weeks Administration - A Case ReportFabrizio Martora, Maria Carmela Annunziata, Luca Potestio, et al.
Journal of Clinical Medicine|September 13, 2025
The Use of JAK Inhibitors in Elderly Patients with Moderate-to-Severe Atopic Dermatitis: A Narrative Review of Clinical and Real-World EvidenceGiuseppe Lauletta, Daniele Cecere, Luca Potestio, et al.
Clinical and Experimental Dermatology|June 26, 2026
Treatment Trajectories and Dose Optimization of Abrocitinib in Moderate-to-Severe Atopic Dermatitis: A Real-World Landmark AnalysisMaddalena Napolitano, Chiara Palagiano, Cataldo Patruno, et al.
Expert Opinion on Pharmacotherapy|November 18, 2021
Alitretinoin for the treatment of severe chronic eczema of the handsMaddalena Napolitano, Luca Potestio, Mario De Lucia, et al.
Pageof 14

Showing results (51-60 of 138) with videos related to

Sort By:
Pageof 14
Journal of Inflammation Research|February 19, 2026
IL-23 Inhibitors in Psoriasis: What Have We Learnt so Far?Matteo Megna, Michela D'Agostino, Federica Feo, et al.
Clinical, Cosmetic and Investigational Dermatology|February 13, 2023
Efficacy and Safety of Tildrakizumab in a Patient with Chronic HBV InfectionLuca Potestio, Ilaria Piscitelli, Gabriella Fabbrocini, et al.
Clinical and Experimental Dermatology|October 14, 2024
Impact of tildrakizumab on the quality of life of patients with moderate-to-severe psoriasis: a 36-week prospective monocentric real-life observational studySara Cacciapuoti, Teresa Battista, Luca Potestio, et al.
Clinical, Cosmetic and Investigational Dermatology|April 15, 2024
The Role of Interleukin 23/17 Axis in Psoriasis Management: A Comprehensive Review of Clinical TrialsLuca Potestio, Fabrizio Martora, Giuseppe Lauletta, et al.
Clinical and Experimental Dermatology|April 24, 2024
Efficacy and safety of bimekizumab in real-world psoriasis management: data from patients who are biologic-naive vs. biologic-experiencedMatteo Megna, Angelo Ruggiero, Ginevra Torta, et al.
Clinical, Cosmetic and Investigational Dermatology|March 13, 2024
Long-Term Efficacy of Guselkumab in an Adolescent Hidradenitis Suppurativa Patients: A Case ReportFabrizio Martora, Teresa Battista, Luca Potestio, et al.
Clinical, Cosmetic and Investigational Dermatology|June 4, 2024
Secukinumab for Severe Hidradenitis Suppurativa in a Patient on Haemodialysis: Efficacy and Safety on 300 mg Every 2 Weeks Administration - A Case ReportFabrizio Martora, Maria Carmela Annunziata, Luca Potestio, et al.
Journal of Clinical Medicine|September 13, 2025
The Use of JAK Inhibitors in Elderly Patients with Moderate-to-Severe Atopic Dermatitis: A Narrative Review of Clinical and Real-World EvidenceGiuseppe Lauletta, Daniele Cecere, Luca Potestio, et al.
Clinical and Experimental Dermatology|June 26, 2026
Treatment Trajectories and Dose Optimization of Abrocitinib in Moderate-to-Severe Atopic Dermatitis: A Real-World Landmark AnalysisMaddalena Napolitano, Chiara Palagiano, Cataldo Patruno, et al.
Expert Opinion on Pharmacotherapy|November 18, 2021
Alitretinoin for the treatment of severe chronic eczema of the handsMaddalena Napolitano, Luca Potestio, Mario De Lucia, et al.
Pageof 14